Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
6.37
-0.23 (-3.48%)
At close: Nov 18, 2025, 4:00 PM EST
6.43
+0.05 (0.86%)
After-hours: Nov 18, 2025, 4:07 PM EST
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 33 employees as of December 31, 2024. The number of employees increased by 4 or 13.79% compared to the previous year.
Employees
33
Change (1Y)
4
Growth (1Y)
13.79%
Revenue / Employee
n/a
Profits / Employee
-$960,907
Market Cap
325.51M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33 | 4 | 13.79% |
| Dec 31, 2023 | 29 | 8 | 38.10% |
| Dec 31, 2022 | 21 | 0 | - |
| Dec 31, 2021 | 21 | 9 | 75.00% |
| Dec 31, 2019 | 12 | 0 | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
EPRX News
- 5 days ago - Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI - GlobeNewsWire
- 14 days ago - Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs - GlobeNewsWire
- 7 weeks ago - Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option - GlobeNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Announces Pricing of US$70 Million Public Offering of Common Shares - GlobeNewsWire
- 2 months ago - Eupraxia Pharmaceuticals Announces Proposed Public Offering of Common Shares - GlobeNewsWire
- 3 months ago - Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences - GlobeNewsWire